Intracerebroventricular injection of human prostatic acid phosphatase has potent neuroprotective effects against transient focal cerebral ischemia in rats
Intracerebroventricular injection of human prostatic acid phosphatase has potent neuroprotective effects against transient focal cerebral ischemia in rats
复制标题
脑室内注射人前列腺酸性磷酸酶对大鼠短暂性局灶性脑缺血具有有效的神经保护作用
DOI：
10.1016/j.neulet.2011.09.057
复制
发表时间：
2011-10-31
影响因子：
2.5
通讯作者：
Xiong, Lize
中科院分区：
文献类型：
--
作者：
Yang, Yue;Bai, Xiaoguang;Xiong, Lize
虽然腺苷作为神经保护剂的潜在用途早已被认识到，但目前还没有用于预防或治疗脑缺血和再灌注损伤的基于腺苷的疗法。前列腺酸性磷酸酶（PAP）是一种长期以来作为前列腺癌诊断标志物的酶，最近已被证明表现出外-5'-核苷酸酶活性，并将内源性细胞外AMP脱磷酸化为腺苷。因此，我们测试的假设，PAP对大脑中动脉闭塞大鼠模型的脑缺血具有持续和有效的神经保护作用。我们发现，hPAP产生了显着的神经保护局灶性脑缺血，明显减少脑梗死和神经功能缺损。hPAP治疗大鼠局灶性脑缺血模型的时间窗为缺血前6 h至再灌注后1.5 h。本研究提示PAP是一种潜在的预防和治疗脑缺血性损伤的药物，尤其是在围手术期。(C)2011爱思唯尔爱尔兰有限公司保留所有权利。
Though the potential use of adenosine as a neuroprotective agent has long been realized, there are currently no adenosine-based therapies for the prevention or treatment of cerebral ischemia and reperfusion injury. Prostatic acid phosphatase (PAP), an enzyme that has long served as a diagnostic marker for prostate cancer, has been recently demonstrated to exhibit ecto-5'-nucleotidase activity, and dephosphorylate endogenous extracellular AMP to adenosine. We therefore tested the hypothesis that PAP has sustained and potent neuroprotective effects against cerebral ischemia in the rat model of middle cerebral artery occlusion. We found that hPAP produced significant neuroprotection against focal cerebral ischemia, as evident from significant reduction in cerebral infarction and neurological deficits. The therapeutic time window for hPAP in rat focal cerebral ischemia model was limited from 6 h before ischemia to 1.5 h after reperfusion. The present study suggested that PAP is a potential candidate for the prevention and treatment of cerebral ischemic injury, especially during perioperative period. (C) 2011 Elsevier Ireland Ltd. All rights reserved.